Liquid biopsy companies develop minimally invasive tests that analyse tumour-derived and other disease-associated material found in blood or bodily fluids. These technologies support earlier detection, treatment selection, response monitoring and the identification of disease recurrence.
This category includes companies working on:
Browse 33 UK liquid biopsy companies below.
Cambridge cancer research institute advancing discovery and clinical translation
Cancer Research UK Cambridge Institute is a cancer research institute within the University of Cambridge, investigating tumour biology, early detection and treatment. Its research groups study cancer evolution, genomics and the tumour microenvironment, using imaging and computational approaches to improve diagnosis…
Liquid biopsy platform for isolating circulating tumour cells
Vortex Biosciences develops liquid biopsy technology for isolating circulating tumour cells from whole blood. Its automated, non-contact approach is designed to recover intact, viable cells that can be studied after collection. Preserving cell viability is important for molecular and functional analysis, rather than…
Circulating tumour cell liquid biopsy technology for cancer research and diagnostics
CelLBxHealth is a Guildford-based liquid biopsy company that develops and manufactures microfluidic circulating tumour cell harvesting technology and provides associated laboratory services. Its FDA-cleared instrument captures intact circulating tumour cells from blood samples for downstream genomic, transcriptomic,…
Cancer genetics testing and contract research
Oncologica provides molecular cancer diagnostics and contract research services from its laboratory at Chesterford Research Park near Cambridge. Its Oncofocus testing uses tumour DNA profiling to help clinicians identify potentially relevant targeted treatments and immunotherapies. The company also develops…
Cell-free DNA capture reagents for liquid biopsy and cancer diagnostics
BIOCAPTIVA is a biotechnology company developing novel cell-free DNA capture technology to improve liquid biopsy for cancer research and diagnostics. Its proprietary polymer platform captures cfDNA directly from whole blood without centrifuges or additional reagents, delivering substantially higher cfDNA yields than…
Organ-specific liquid biopsy tests for early cancer detection
Mursla Bio is a diagnostics company developing blood-based tests for early cancer detection using extracellular vesicle biology. Its platform isolates organ-specific extracellular vesicles from blood and applies multi-omics profiling and machine learning to identify disease biomarkers without tissue biopsy. Its lead…
Multiomics platform for cancer biomarker discovery and diagnostics
Tagomics is a Cambridge-based biotech developing a multiomics platform for disease biomarker discovery and diagnostics. Its platform integrates genomics, epigenomics and fragmentomics with advanced bioinformatics and machine learning to identify disease-associated DNA markers from blood and other biological sources.…
Custom qPCR, digital PCR and amplicon sequencing reagents
SHARD DIAGNOSTICS is a Nottingham molecular diagnostics company developing and manufacturing PCR assay reagents and bespoke molecular testing kits. Its technologies support quantitative and digital PCR, multiplex detection and amplicon sequencing, including inhibitor-tolerant and lyophilised formulations. Applications…
Molecular diagnostic kits and genomic services for clinical laboratories
Yourgene Health is a molecular diagnostics company developing, manufacturing and commercialising IVD reagent kits and genomic services for reproductive health, precision medicine and infectious disease. Its product portfolio includes NGS-based non-invasive prenatal testing kits, cystic fibrosis screening assays,…
NGS liquid biopsy testing for cancer in dogs and cats
CanCan Diagnostics is a veterinary biotechnology company developing next-generation sequencing tests for cancer detection and monitoring in companion animals. Its K9 LiquiDx liquid biopsy analyses tumour-associated mutations in circulating cell-free DNA from canine blood samples. The company also offers tissue-based…
Molecular diagnostic assay development for oncology biomarkers
APIS Assay Technologies is a molecular diagnostics company developing and commercialising genomic assays for oncology and personalised medicine. The company combines an in-house biomarker research programme with contract assay development services, using PCR, digital PCR, and multi-omics platforms to translate…
Multiomics blood-based platform for early-stage cancer detection
Freenome is a biotechnology company developing blood-based early cancer detection tests using a multiomics platform that combines tumour and non-tumour biological signals with machine learning. The UK subsidiary, based in Nottingham, holds the autoantibody immunodiagnostic technology and cancer detection pipeline…
Enzyme-free multiplex RNA diagnostics for rapid clinical decisions
Cambridge Nucleomics is a biotechnology company developing a proprietary nanopore-based platform for rapid, high-multiplexed detection of nucleic acid biomarkers. Its enzyme-free soluble nanoarray technology enables simultaneous quantification of up to 200 RNA and DNA targets from low-input samples within one hour.…